stephenatlanta Posted - 5 hours ago

$KURA Sitting on the price of last funding raise with gap below. Brakes here could get a flush. No position.

GPS_OS_21_vs_SOC_5 Posted - 22 hours ago

$SLS The LYING Scumbag POS, Bill William Walker, aka @telomerase knows the only reason CDK9 Inhibitors haven't Yet Been Approved is due to Off Target Toxicity. SLS009 - is the Most Advanced, Next Gen 100x More Selective CDK9 and has had NO Dose Limiting Toxicity nor any Serious Side Effects, not 1 Serious Side effect in over 150 Patients Treated. 009 is now in 3 Phase 2 Trials with 100% Response Rates in Advanced End Stage AML Patients - Median OS has not yet been reached, and is already 250% longer than SOC. $KURA Also in P2 AML subset is worth $1.4B --- 1.4B based solely on ints P2 Menin Inhibitor - achieved 40% response topline data. 009 is at 100%. and all of $SLS only trades for $80M and 009 is just the "Secondary Asset". Do some DD on this Comp vs 009 you will load as many as you can hold https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-reports-positive-preliminary-ziftomenib#:~:text=As%20of%20the%20data%20cutoff%20on%20January%2011%2C,NPM1-m%20AML%20and%20one%20patient%20with%20KMT2A-r%20AML.

xbibackto70s Posted - 2 days ago

$KURA gap fill coming ? 15?

GPS_OS_21_vs_SOC_5 Posted - 4 days ago

$SLS While we wait for the Imminent, Binary, Unblinded, PH3 Results worth multiple Billion, - any day now AH or Pre, this is a great link for some DD on a direct market comp for 009. $KURA in P2 for R/R Aml nmp1/kmta subset $1.6B Mcap - 009 3 P2’s .069b https://stocks.apple.com/A2ITFjErSS9SnYfHkQf3uBQ

GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$SLS PS anytime you see @expharmaCon lying about 009 being "early", know its a lying short con. $KURA Published Phase 2 top line trial results in Q1 for its Menin Inhibitor Ziftomenib, 40% CR rates for an AML subset, its worth $1.6B. This is -- > KURA is worth 1.6b based on p2 topline, and still enrolling the p2. 009 has 100% Complete Response rates for biomarker positive AML patients, trades for $0.07B. -- not for much longer. $KRON take note: 009 CDK9 Inhibitor, NO DLT's, No Serious Side Effects, 100% CR Rates for MUC and MYC1.

GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$SLS Its APRIL 10 -- The good news, bad news is, none of the value for the phase 3 results are priced in to the stock, not 1 nickel, and sls' secondary asset is worth 20x the current share price. 100% response rates for end stage dying aml patients ... 40% response rates in P2 are worth $1.6B for $KURA. Shorts have manipulated this share price to 1/100th the actual value, while hedging options to protect themselves. BE HOLDING AS MANY AS YOU CAN.

Stock_Titan Posted - 1 week ago

$KURA Kura Oncology to Participate in Stifel Targeted Oncology Forum https://www.stocktitan.net/news/KURA/kura-oncology-to-participate-in-stifel-targeted-oncology-w8oamgtirrxw.html

Galarius Posted - 1 week ago

$KURA $SLS $VINC right on

GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$VINC 100% CR Rates for End stage, Dying AML Patients. A Not Yet Met Median OS of 6+ months, in the Low Dose Cohort, for these patients who have a 2.5/3 month life expectancy. Median OS of 6+ months is already 250% longer than SOC, and this is in the Low Dose 45 Mg Cohort. Results will only get Better $KURA currently enrolling a P2 for KMTa/nmpa AML subset, has a $1.6B MCAP $SLS Currently enrolling a P2 for AML mainline Patients $.07B MCAP - Massively undervalued equity, Just Raised cash. Mark this post. SLS will be a Billion Dollar Company in Q2. https://www.biospace.com/article/releases/sellas-announces-positive-topline-data-from-the-phase-2a-study-of-sls009-in-r-r-aml-and-provides-steering-committee-update-on-phase-3-regal-study/ $SLS

GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$SLS We are going to see several days with +100% share price increases. - this $75m mcap is by all metrics worth 100X more +’when the Imminent Phase 3 results are announced. - Celator was a $50M mcap the day it released its P3 aml trial results, it was a $750M mcap 3 weeks later, then got bought by $jazz for $1.6B, 6 weeks after that. - something very similar will be happening here. Imminently. imp note, Gps Immunotherapy will treat 5x the number of patients $cpxx's drug does. - even the "secondary" SLS asset, 009 has a market comp, $KURA , at the same stage of P2 development worth $1.6B - DD $XBI $VINC

GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$SLS - Massive ROI on The Table What will SLS be worth the moment the IMMINENTLY Due, FDA Registrational, P3 Results are Announced? - There are known data points and facts that allow anyone to estimate value: - 10,000 CR2 patents, on the SLS Corp Deck Market Scope - Cco published $260K per pricing comps - another 15K 1st remission - $2.6B TAM just the initial 10K Cr2 patients - Big Pharma Trade at 4x Price to Sales ratio's - Conceivably, GPs is worth 4x $2.6b = $10.4B Max to BP - then add CR1, another $15B - then add Mesothelioma 3K - Ovarian Cancer 12K - 009 $kura is a $1.7b P2 comp Compare all that to the current short manipulated $.075B mcap. - Massive ROI on The Table -Once we Get the PH 3 Trial Results Confirming EFFICACY, Gps' BLA is assured, given its pristine safety profile near 100% QoL and the recent positive Fda type C (CMC) meeting in dec. The Imminent P3 Readout Is Binary. $XBI

GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$SLS The Phase 3 Results are Imminent and Could be Announced any day according to the REGAL Steering Committee Dr. Kantarjian, Ybarra and Levy. - What will SLS be worth the moment the Imminently Due P3 Results are Announced? - Once we Get the PH 3 Trial Results Confirming EFFICACY, Gps' BLA is assured, given its pristine safety profile near 100% QoL and the recent positive Fda type C (CMC) meeting in dec. The Imminent P3 Readout Is Binary. - There are known data points and facts that allow anyone to estimate value: 10,000 CR2 patents, on the SLS Corp Deck Market Scope They published 260K per pricing comps another 15K for first remission $2.6B TAM just the initial 10K Cr2 patients Big Pharma Trade at 4x Price to Sales ratio's - Conceivably, GPs is worth 4x 2.6 = 10.4B Max to BP - then add CR1, another $15B - then add Mesothelioma - Ovarian Cancer - 009 Compare all that to the current short manipulated $.075B mcap. $ATNM $KURA $KRON $VINC

Johnmtnb2018 Posted - 1 week ago

$JAZZ $KURA $SLS Imminent 🙌💎🙌

GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$JAZZ $SLS We are going to see several days with +100% share price increases. - this $70M mcap is by all metrics worth 100X + more, when the Imminently Due p3 results are announced. Any Day Now. - even SLS's "secondary" asset, 009 has a market comp, $kura, at the same stage of P2 development worth $1.7B. - Seriously do a bit of dd on ziftomenib, enrolling a PH2, a menin inhibitor for nmp1 / kmta aml subset patients.

GPS_OS_21_vs_SOC_5 Posted - 2 weeks ago

$SLS Smart Money, is buying every cheap share they can right now, while it's quiet, before the Phase 3 news hits hard and starts the bull herd running. Gps is worth $10B when the P3 comes in. No manipulation will be able to change that. 009, the first ever safe CDK9 Inhibitor, just announced 100% CR Rates for end stage, dying AML patients, has a $1.7B PH2 comp $KURA reported Top Line P2 Data in Jan, still enrolling their P2 for an AML subset. Just facts.

Stock_Titan Posted - 2 weeks ago

$KURA Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-nvj4hpp4yevq.html

GPS_OS_21_vs_SOC_5 Posted - 2 weeks ago

$SLS Massive Upside in SLS now, partly due to the years long short manipulation. Share Price will be climbing every day we wait for the IMMINENTLY DUE PHASE 3 RESULTS - This $67M of manipulated equity is about to get an Fda green light worth multiple billions - the definition of imminent is 'about to happen'. - and the kicker, is SLS's secondary asset 009, the first ever Safe CDK9 Inhibitor, just reported 100% CR Rates For DYING AML Patients, has a direct market comp, $KURA, enrolling a P2, worth $1.7B. Seriously. dd

GPS_OS_21_vs_SOC_5 Posted - 2 weeks ago

$SLS $KURA Just 009 could be worth 40x the current short manipulated market cap. - 009 is on par developmentally with kura's menin inhibitor now enrolling a P2. - mcap $1.7B - 2 Years ago $vinc was worth $500M based solely on the potential efficacy of its P1 CDK9 Asset, VIP150/2 before the Tox became evident. 009 is the Real Deal. -- Re 009 update: the 45mg low dose results will show a not yet met, median os of at least 6 months, based on previous data. 6+ months vs only 2.5/3 w soc, already double the survival and the max dose 60mg results will be even better. anyone doing dd. - a great comp for sls009 is the menin Inhibitor Ziftomenib, for AML NMP1 subset patients, currently enrolling phase 2 and is worth $1.67b - yes a b, for this P2 asset. $kura.

GPS_OS_21_vs_SOC_5 Posted - 2 weeks ago

$SLS $57M 009 Compare the Jan 2024 $KURA ($1.7B)Top Line Phase 2 Result of 40% CR in kmta biomarker r/r aml, —- to the March Top Line 009, Phase 2 100% CR in End stage r/r Aml biomarker patients. 20X + Upside Just in SLS Just for 009, the secondary asset. sls shares have been manipulated way below fair value.

GPS_OS_21_vs_SOC_5 Posted - 03/28/24

$SLS 100% CR Rates for Biomarker Positive, max dose 009, End Stage Dying AML Patients - 100% patients who have failed and are refractory to AZA DECI - VEN combinations have a 2.5 MOS. Not Yet Met MOS for the low dose 009 patients is already greater than 6 months! $KURA Ziftomenib achieved a 40% CR Rate is worth $1.67B $55M MCAP LOL

GPS_OS_21_vs_SOC_5 Posted - 03/27/24

$SLS mcap $54M and this is the secondary asset - - $kura achieved a top line orr of 40% in an aml subset ph2 trial, $1.67b mcap -- SLS009 achieved a top line orr of 50% in AML mainline ph2 trial, $0.054b mcap -- SLS009 achieved 100% orr in the biomarker positive, end stage dying aml patients. -- dr's kadia and zeidner were clear, 009 only needed a 25% orr to become the standard of care for this setting. -- $SNDX Just Hit its Goal of 23% CR ... 009 is at 100% for biomarker Positive - hence the short n distort team https://finance.yahoo.com/news/syndax-announces-fda-priority-review-200500747.html

GPS_OS_21_vs_SOC_5 Posted - 03/27/24

$SLS - Now that we Know from the Steering Committee, Dr. Kantarjian, Ybarra and Levy, the PH3 Results are Imminent and Could be Announced any day - What will SLS be worth when Gps gets the Fda Green light? -- note: Once we Get the PH 3 Trial Results Confirming EFFICACY, Gps' BLA is assured, given its pristine safety profile, and the recent positive fda type C (CMC) meeting in dec. The Imminent P3 Readout Is Binary. - My take There are known data points and facts that allow anyone to estimate value: 10,000 CR2 patents, on the SLS Corp Deck Market Scope They published 260K per pricing comps another 15K for first remission $2.6B TAM just the initial 10K Cr2 patients Big Pharma Trade at 4x Price to Sales ratio's - Conceivably, GPs is worth 4x 2.6 = 10.4B Max to BP - then add CR1, another $15B - then add Mesothelioma - Ovarian Cancer - 009 Compare all that to the short manipulated $.057B $ATNM $KURA $KRON $VINC

NEWBIGTECH Posted - 03/26/24

$SLS $ATNM $KURA $KRON $VINC

GPS_OS_21_vs_SOC_5 Posted - 03/26/24

$SLS love seeing the Steering Committee, which includes Dr Hagop Kantarjian, the Chair of MD Andersons Leukemia Dept., stating this Binary, Multi-Billion Dollar Fda Registrational PH 3 result is IMMINENT. $ATNM $KURA $KRON $VINC

GPS_OS_21_vs_SOC_5 Posted - 03/26/24

$SLS There are known data points and facts that allow anyone to estimate value: 10,000 CR2 patents, on the SLS Corp Deck Market Scope They published 260K per pricing comps another 15K for first remission 2.6B TAM just the initial 10K Cr2 patients Big Pharma Trade at 4x Price to Sales ratio's - Conceivably, GPs is worth 4x 2.6 = 10.4B Max to BP - then add CR1, another 15B - then add Mesothelioma - Ovarian Cancer - 009 $SLS Compare all that to .057B $ATNM $KURA $KRON $VINC

GPS_OS_21_vs_SOC_5 Posted - 03/26/24

$SLS Gps Phase 3 Imminent Huge ROI on a very short string, could be any day now from here til end of APRIL And - 100% ORR For end stage Dying AML Patients 009 is officially worth as much as $KURA The intrinsic value mismatch with the share price/market is reminiscent of when $VINC was sitting at $1 before it jumped to $9 in a couple of weeks $ATNM $KRON

GPS_OS_21_vs_SOC_5 Posted - 03/26/24

$SLS - $kura $1.67B mcap, achieved a PH2 top line ORR of 40% in an AML subset -$SLS .054B mcap achieved a PH2 topline ORR of 50% in AML mainline patients SLS SHARE PRICE WILL BE CLIMBING - 100% response rate for biomarker positive patients, 50% orr for all patients - per Dr Kadia and Ziedner, all 009 needed was 25% to become Standard of Care. -- Safe -- current treatment environment 2.5months of OS vs a not yet met median os w 009 And for those who don't know, dosing began in June 2023 ended in dec 2023 - first dosed in patient is now in complete remission, and continues to survive. - 3 to 9 month range - so at a minimum 009 OS is double 6+ months.

Doorkey Posted - 03/26/24

$KURA There's money here.

GPS_OS_21_vs_SOC_5 Posted - 03/25/24

$SLS Just 009 could be worth 40x the current short manipulated market cap. - If the ceo says the word registrational, it will put this CDK9 inhibitor on par with kura's menin inhibitor now enrolling a P2. - mcap $1.7B - 2 Years ago $vinc was worth $500M based solely on the potential efficacy of its P1 CDK9 Asset, VIP150/2 before the Tox became evident. 009 is the Real Deal. -- Re 009 update: the 45mg low dose results will show a not yet met, median os of at least 6 months, based on previous data. 6+ months vs only 2.5/3 w soc, already double the survival and the max dose 60mg results will be even better. anyone doing dd. - a great comp for sls009 is the menin Inhibitor Ziftomenib, for AML NMP1 subset patients, currently enrolling phase 2 and is worth $1.67b - yes a b, for this P2 asset. $kura.

GPS_OS_21_vs_SOC_5 Posted - 03/25/24

$SLS can't imagine the short interests not covering, and or hedging, before this P3 data is announced... on Tuesday. -- $1.10 stock could be worth nearly 100 dollars ... do the math - shorts are staring at Insane Losses. 5 years of trial development, due now in Q1. A positive result and Gps gets the green light to treat 25,000 patients each year - The co published $260K Per patient pricing comps - a bonafide $6B TAM -- this Manipulated $57M MCAP will be worth many Billions -- and $kura is Direct Market comp for 009 P2 results that are going to be announced. And From known data points, the few of us paying attention can already deduce the results, (like the Funds that just paid $20M at $1.54 in the Registered Direct Offering) - We will see at least a Doubling of Survival Over the SOC with a Not Yet Met Median OS of 6+ months, double the SOC Life Expectancy of 2.5/3months.